AnaptysBio Inc (NASDAQ:ANAB) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $111.42 and last traded at $103.52, with a volume of 284100 shares trading hands. The stock had previously closed at $102.57.

ANAB has been the topic of a number of research reports. Wedbush reissued a “positive” rating and issued a $82.00 price objective (up from $75.00) on shares of AnaptysBio in a report on Tuesday, November 7th. Robert W. Baird set a $69.00 price objective on AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $76.00 price objective (up from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. Finally, Credit Suisse Group increased their price objective on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $88.00.

The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $2,530.00 and a price-to-earnings ratio of -72.98.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. analysts expect that AnaptysBio Inc will post -1.72 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of ANAB. Evercore Wealth Management LLC purchased a new stake in shares of AnaptysBio in the third quarter worth about $100,000. Legal & General Group Plc boosted its stake in shares of AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock worth $110,000 after buying an additional 1,951 shares during the last quarter. DAFNA Capital Management LLC boosted its stake in shares of AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after buying an additional 1,000 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in shares of AnaptysBio in the second quarter worth about $168,000. Finally, Nationwide Fund Advisors boosted its stake in shares of AnaptysBio by 89.5% in the third quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock worth $205,000 after buying an additional 2,776 shares during the last quarter. Hedge funds and other institutional investors own 75.48% of the company’s stock.

TRADEMARK VIOLATION WARNING: “AnaptysBio (ANAB) Hits New 12-Month High at $111.42” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/01/12/anaptysbio-anab-hits-new-12-month-high-at-111-42.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Stock Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related stocks with our FREE daily email newsletter.